Primmune Therapeutics, Inc.
JLABS San Diego 3210 Merryfield Row
San Diego, CA 92121
Biotech and Pharmaceutical
Primmune Therapeutics is developing an orally administered agonist to stimulate innate immunity in cancer immunotherapy. This innate immunity stimulator is highly complementary to and is expected to be useful in combination with other immunotherapies including (i) checkpoint inhibitors and related agents (e.g., IDO, tyrosine kinase inhibitors and other), (ii) antibody and antibody-like therapeutics, (iii) therapeutic vaccines, and (iv) cellular therapeutics